L-Arginin-N,N-dimethylamid | 609367-47-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Arginin-N,N-dimethylamid
• 英文别名: (2S)-2-amino-5-(diaminomethylideneamino)-N,N-dimethylpentanamide
• CAS: 609367-47-7
• 化学式: C₈H₁₉N₅O
• 分子量: 201.272
• InChiKey: MHLWCHJULZWDEK-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  L-Arginin-N,N-dimethylamid 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethyl-carbamoyl-4-guanidinobutyl)-amide
  参考文献：
  名称：

  Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains

  摘要：

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00533-x
• 作为产物：
  描述：

  N-苄氧羰基-L-精氨酸 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 L-Arginin-N,N-dimethylamid
  参考文献：
  名称：

  Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains

  摘要：

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00533-x

文献信息

• [EN] MEXILETINE PRODRUGS<br/>[FR] PROMÉDICAMENTS DE MÉXILÉTINE
  申请人：SHIRE LLC

  公开号：WO2012085586A1

  公开（公告）日：2012-06-28

  The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse G1 side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.

  本发明涉及美西利汀（及美西利汀的活性代谢物）的前药，包含这些前药的药物组合物。还提供了用于治疗肌张力疾病的方法，同时减少与美西利汀相关的固有不良G1副作用，增加美西利汀的生物利用度，并通过上述前药改善美西利汀的药代动力学可重复性。
• MEXILETINE PRODRUGS
  申请人：Franklin Richard

  公开号：US20120196933A1

  公开（公告）日：2012-08-02

  The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.

  本发明涉及美西律定（以及美西律定的活性代谢物）的前药以及含有这些前药的药物组合物。还提供了治疗肌张力不良症的方法，同时减少与美西律定相关的固有不良胃肠副作用，增加美西律定的生物利用度，并改善美西律定的药代动力学可重复性。
• Stoffwechseleffekte von Argininderivaten, III. Insulinähnliche Aktivität von L-Arginin-<i>N</i>,<i>N</i>-dialkylamiden in vitro
  作者：Günther Weitzel、Wieland Stock、Hans Guglielmi

  DOI：10.1515/bchm2.1972.353.2.1661

  日期：1972.1
• Structure–activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains
  作者：Stephen J. Davies、Andrew P. Ayscough、R.Paul Beckett、John M. Clements、Sheila Doel、Lisa M. Pratt、Zoë M. Spavold、S.Wayne Thomas、Mark Whittaker

  DOI：10.1016/s0960-894x(03)00533-x

  日期：2003.8

  Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2' and P3' side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2' and P3' positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2' and P3' positions to optimise the physicochemical properties. (C) 2003 Elsevier Ltd. All rights reserved.